Skip to content

Study · Randomized controlled trial · n = 12 · 2002

6 results

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus.

Vella A, Lee JS, Camilleri M, Szarka LA, Burton DD, Zinsmeister AR, Rizza RA, Klein PD

Neurogastroenterology and motility1 Apr 2002Cited by 79 (Europe PMC)

PMID11975712 (opens in a new tab)DOI10.1046/j.1365-2982.2002.00311.x (opens in a new tab)PepBankPUB-11975712
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In type 1 and type 2 diabetes, pramlintide increased gastric emptying half-time to 268 minutes versus 91 minutes with placebo.

    In plain wordsIn type 1 and type 2 diabetes, lower-dose pramlintide delayed stomach emptying compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseGastric emptying half-time, lower dose
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    30 microg t.i.d. · subcutaneous · 5 daysAs given in this study (human).

    Measurements

    Gastric emptying t50%
    268 min
    pramlintide 30 microg t.i.d. (SEM 37)
    Gastric emptying t50%
    91 min
    placebo (SEM 6)

    Source sentences

    Summary
    Relative to placebo [t 50% 91 +/- 6 min (means +/- SEM)], pramlintide equally delayed gastric emptying following 30 or 60 microg t.i.d. (268 +/- 37 min, 329 +/- 49 min, respectively; P < 0.01].
    1 context sentence
    Summary · context
    Using a randomized, three-period, two-dose, crossover design, we studied the effects of 0, 30, or 60 microg t.i.d. pramlintide subcutaneously for 5 days each in six type 1 and six type 2 diabetic subjects.
  2. 02HumanRandomized controlled trialMechanism

    In type 1 and type 2 diabetes, pramlintide increased gastric emptying half-time to 329 minutes versus 91 minutes with placebo.

    In plain wordsIn type 1 and type 2 diabetes, higher-dose pramlintide delayed stomach emptying compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseGastric emptying half-time, higher dose
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    60 microg t.i.d. · subcutaneous · 5 daysAs given in this study (human).

    Measurements

    Gastric emptying t50%
    329 min
    pramlintide 60 microg t.i.d. (SEM 49)
    Gastric emptying t50%
    91 min
    placebo (SEM 6)

    Source sentences

    Summary
    Relative to placebo [t 50% 91 +/- 6 min (means +/- SEM)], pramlintide equally delayed gastric emptying following 30 or 60 microg t.i.d. (268 +/- 37 min, 329 +/- 49 min, respectively; P < 0.01].
    1 context sentence
    Summary · context
    Using a randomized, three-period, two-dose, crossover design, we studied the effects of 0, 30, or 60 microg t.i.d. pramlintide subcutaneously for 5 days each in six type 1 and six type 2 diabetic subjects.
  3. 03HumanRandomized controlled trialMechanism

    In type 1 and type 2 diabetes, pramlintide at 30 microg lowered postprandial pancreatic polypeptide compared with placebo.

    In plain wordsIn type 1 and type 2 diabetes, lower-dose pramlintide lowered pancreatic polypeptide after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial pancreatic polypeptide, lower dose
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Endogenous peptide levels · Gastrointestinal
    Studied dose
    30 microg t.i.d. · subcutaneous · 5 daysAs given in this study (human).

    Source sentences

    Summary
    Postprandial HPP levels were lower in response to 30 and 60 microg pramlintide compared to placebo.
    1 context sentence
    Summary · context
    Using a randomized, three-period, two-dose, crossover design, we studied the effects of 0, 30, or 60 microg t.i.d. pramlintide subcutaneously for 5 days each in six type 1 and six type 2 diabetic subjects.
  4. 04HumanRandomized controlled trialMechanism

    In type 1 and type 2 diabetes, pramlintide at 60 microg lowered postprandial pancreatic polypeptide compared with placebo.

    In plain wordsIn type 1 and type 2 diabetes, higher-dose pramlintide lowered pancreatic polypeptide after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial pancreatic polypeptide, higher dose
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Endogenous peptide levels · Gastrointestinal
    Studied dose
    60 microg t.i.d. · subcutaneous · 5 daysAs given in this study (human).

    Source sentences

    Summary
    Postprandial HPP levels were lower in response to 30 and 60 microg pramlintide compared to placebo.
    1 context sentence
    Summary · context
    Using a randomized, three-period, two-dose, crossover design, we studied the effects of 0, 30, or 60 microg t.i.d. pramlintide subcutaneously for 5 days each in six type 1 and six type 2 diabetic subjects.

Studies that did not test the peptide alone2

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 05HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialMechanism

    Pramlintide effects on gastric emptying did not differ significantly between type 1 and type 2 diabetes.

    In plain wordsPramlintide affected stomach emptying similarly in type 1 and type 2 diabetes.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeGastric emptying effect by diabetes type
    Study

    n = 12

    Comparator
    Type 1 versus type 2 diabetes
    Outcome group
    Gastrointestinal motility · Gastrointestinal

    Source sentences

    Summary
    There were no significant differences in the effects on gastric emptying or HPP levels between type 1 and type 2 diabetic subjects.
    1 context sentence
    Summary · context
    Using a randomized, three-period, two-dose, crossover design, we studied the effects of 0, 30, or 60 microg t.i.d. pramlintide subcutaneously for 5 days each in six type 1 and six type 2 diabetic subjects.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 06HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialMechanism

    Pramlintide effects on pancreatic polypeptide levels did not differ significantly between type 1 and type 2 diabetes.

    In plain wordsPramlintide affected pancreatic polypeptide levels similarly in type 1 and type 2 diabetes.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changePancreatic polypeptide effect by diabetes type
    Study

    n = 12

    Comparator
    Type 1 versus type 2 diabetes
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    There were no significant differences in the effects on gastric emptying or HPP levels between type 1 and type 2 diabetic subjects.
    1 context sentence
    Summary · context
    Using a randomized, three-period, two-dose, crossover design, we studied the effects of 0, 30, or 60 microg t.i.d. pramlintide subcutaneously for 5 days each in six type 1 and six type 2 diabetic subjects.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.